title: Evaluation of subretinal triamcinolone acetonide in patients with exudative age-related macular degeneration.
abstract: OBJECTIVE
  The aim of this paper was to present the results of subretinal delivery of triamcinolone acetonide (TCA) in humans with choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD).
  
  
  METHODS
  Twenty two (22) eyes of 22 patients underwent pars plana vitrectomy with subretinal TCA administration. Two milligrams (2 mg) of preservative-free TCA were delivered through a 32-gauge automatic subretinal injector in 20 microL of volume. Visual acuity, fluorescein angiography (FA), and intraocular pressure (IOP) were recorded and compared pre- and postoperatively.
  
  
  RESULTS
  Preoperative average+/-standard deviation visual acuity in the treated eye was 1.408+/-0.129 (logMAR; median 20/400) and 1.403+/-0.114 (logMAR; median 20/300) postoperatively (P=0.51). The mean area of pre- and postoperative FA leakage in the operated eyes was 21.31+/-1.125 and 19.29+/-1.108 mm2, respectively (P=0.04). The average IOP value before treatment was 15.3+/-0.78 mmHg. Three (3) months after surgery, it was 20.5+/-2.04 mmHg (P=0.02). Six (6) months and 1 year after surgery, the average IOP was 17.0+/-0.66 mmHg (P=0.9) and 15.6+/-1.02 mmHg (P=0.6), respectively.
  
  
  CONCLUSIONS
  Subretinal TCA stabilizes visual acuity, decreases FA leakage in eyes with CNV owing to AMD, and does not increase IOP, as seen with intravitreous injections.
authors.affiliation: Jacobs Retina Center at Shiley Eye Center, University of California at San Diego, La Jolla, CA 92037, USA.
authors.forename: Igor
authors.initials: I
authors.lastname: Kozak
authors.forename: Lingyun
authors.initials: L
authors.lastname: Cheng
authors.forename: Iryna
authors.initials: I
authors.lastname: Falkenstein
authors.forename: Ajay M
authors.initials: AM
authors.lastname: Tammewar
authors.forename: William R
authors.initials: WR
authors.lastname: Freeman
mesh_terms: D000368:Aged; D000375:Aging; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D003131:Combined Modality Therapy; D004596:Electroretinography; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010865:Pilot Projects; D012160:Retina / Q000187:drug effects*; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide